CYLD and neoplasm: Several studies showed that the tumor suppressor CYLD inhibits NF-kB as well as the p38 MAPK pathway activation by deubiquitinating several upstream regulatory signaling molecules of these pathways, thus suppressing these signaling pathways [68].